Melanoma — Trials · CancerIndex

Clinical trials

Registered studies

3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 606
Recruiting: 317
Ph III recruiting: 30
Growth YoY: +37.2%
Industry share: 33%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 37.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (571)

clinicaltrialsPublishedShowing 651–700 of 1,379 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00145158	Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma	terminated	Phase 1 / Phase 2	23	Ludwig Institute for Cancer ResearchOTHER	1	Oct 10, 2022	clinicaltrials
NCT00145145	Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma	terminated	Phase 1 / Phase 2	1	Ludwig Institute for Cancer ResearchOTHER	1	Oct 7, 2022